# Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

> **NCT05691244** · PHASE3 · RECRUITING · sponsor: **Pharmazz, Inc.** · enrollment: 514 (estimated)

## Conditions studied

- Acute Ischemic Stroke
- Cerebral Stroke

## Interventions

- **DRUG:** Drug: Normal Saline
- **DRUG:** Sovateltide

## Key facts

- **NCT ID:** NCT05691244
- **Lead sponsor:** Pharmazz, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2026-09
- **Final completion:** 2026-11
- **Target enrollment:** 514 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05691244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05691244, "Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05691244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*